Posts Tagged ‘Brain Cells’

Drug Helps Brain Grow New Cells

Tuesday, August 24th, 2010

Researchers have found a drug that can help the brain grow new cells, and they said their study may lead to ways to improve experimental Alzheimer’s drugs.

The researchers’ work, done on rodents, builds on findings that all mammals, including humans, make brain cells throughout their lives. Most of these die, but this drug helps more of the baby cells survive and grow to become functioning brain cells.

“We make new neurons every day in our brain,” Andrew Pieper of the University of Texas Southwestern Medical Center in Dallas who worked on the study, said in a telephone interview. “What our compound does is allow more of them to survive.”

The compound is called P7C3 for now, and the researchers have already started tweaking it to make it more effective. They said it seems safe and appears to work even when taken as a pill.

The compound is similar to Medivation and Pfizer experimental Alzheimer’s drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.

It is also similar to some compounds owned by Serono, the researchers said.

Dimebon, originally a Russian-made antihistamine also known as latrepirdine, failed in a clinical trial for Alzheimer’s disease in March.

“For the sake of patients suffering from Alzheimer’s disease, it is hoped that the apparently marginal clinical utility of Dimebon might be enhanced by improvements in both its potency and ceiling of proneurogenic, neuroprotective efficacy,” the researchers wrote.

“If so, our work offers concrete assays for the development of improved versions of these neuroprotective drugs.”

Alzheimer’s gradually destroys the brain and affects 26 million people globally. Drugs, such as Pfizer’s Aricept, improve symptoms only minimally.

The researchers went through 1,000 representative compounds from 300,000 chemicals, pooled them, and administered them to mice. They then dissected the brains to see whether any of the mice had made new cells in the hippocampus, a region of the brain associated with learning and memory.

They eventually narrowed the field to P7C3.

When they gave it to old rats for two months, the elderly rodents did far better than other old rats in learning their way around a water maze.

When dissected, the treated rats turned out to have three times the usual number of newborn neurons in a brain region called the dentate gyrus.

They made a derivative of P7C3 called A20 that worked even better

When the researchers tested Dimebon and the Serono compounds, they found these drugs also stimulated the growth of new brain cells. Being able to target their effects could lead to better drugs to treat Alzheimer’s and perhaps other diseases that destroy brain cells like strokes and amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease.

“This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease,” said Dr. Thomas Insel, director of the National Institute on Mental Health, which helped pay for the study.

http://www.wpgauto.com/

Wpg Auto site

Quality Inn Winnipeg Extended Stay Hotel

Canadian  Fleet

Derrick Dodge

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • SOUTH KOREA - Seoul lifts ban on stem cell research Image via Wikipedia The South Korean bioethics committee has lifted a ban on human stem cell research. The decision will now allow for work on human embryonic stem cells to...
  • Judge stops federal funding of embryonic stem cell research [/caption] Washington -- A U.S. district judge granted a preliminary injunction Monday to stop federal funding of embryonic stem cell research that he said destroys embryos, ruling it went against...
  • Sugar, The Other White Drug I appreciate all your comments on my previous post about sugar addiction. This topic has really got me thinking! I’d like to explore it further. If truth be told, I...
  • Doubt Cast on New Alzheimer's Drugs  Do the new Alzheimer's drugs really work?Apparently not, according to some recent Italian studies.Three drugs, Aricept, Exelon, and Reminyl are being prescribed to patients who are in the  mild to...
  • Brain On Overdrive Throughout this pregnancy I have been a bit cautious. Especially since I know what it's like to suffer a miscarriage, I think that somewhat put a damper on my excitement,...
  • Piloting stem cells presents a challenge for treatments Image via Wikipedia Complications and unanticipated side-effects that have slowed the progression of stem cell studies from the lab to the clinic could soon change, researchers say. For a decade,...
  • Children exposed daily to untested personal-care products (Source: Environmental Working Group) – From baby shampoo to diaper wipes, children are exposed every day to products containing chemicals that have not been assessed for their hazards to children,...

New Drug Shows Promise Growing Brain Cells

Friday, August 20th, 2010

Alzheimer’s patients, brain injury patients, and dementia sufferers may benefit from a newly discovered pill that grows brain cells. The drug, currently labeled P7C3 while it undergoes continued study, appears to provide a safe and effective option that helps support developing brain cells to become viable. Testing done on rats demonstrated that the older rats who had been dosed with P7C3 were capable of learning their way

through a maze when other rats, who had not received the drug, could not. The researchers hope the drug can be used to increase the effectiveness of Alzheimer’s drugs like Dimebon, which recently failed in clinical trials.

“For the sake of patients suffering from Alzheimer’s disease, it is hoped that the apparently marginal clinical utility of Dimebon might be enhanced by improvements in both its potency and ceiling of proneurogenic, neuroprotective efficacy,” the researchers wrote. “If so, our work offers concrete assays for the development of improved versions of these neuroprotective drugs.”

More than 25 million people currently suffer from Alzheimer’s disease, which is a progressive disease that destroys the brain until autonomic functions cease and the sufferer dies. P7C3 represents a hopeful breakthrough in research that could lend itself to other areas of brain trauma treatment, including helping people with ALS (also known as Lou Gehrig’s disease).

Dr. Thomas Insel, director of the National Institute on Mental Health, said, “This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease.” The National Institute on Mental Health helped fund the study.

The rats that were treated with the drug had three times as many developing brain cells. Researchers have since used P7C3 to create a derivative drug called A20 that shows even more promise. When the derivative was combined with Dimebon and Sereno, two test-phase Alzheimer treatments, it caused new brain cell growth stimulation.

http://www.wpgauto.com/

Wpg Auto site

Edmonton 2010 Dodge Journey SE Canada Value Package

Winnipeg Auto Dealer

BC Auto Truck SUV Dealers

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Pill could help reverse effects of Alzheimer’s

Tuesday, August 17th, 2010

A pill that reverses age-related mental decline that affects three-quarters of a million people in the UK may be on the horizon as a result of research on new nerve drugs.

The studies raise the possibility of a cure for memory loss and fading mental faculties in an ageing population, according to experts who stress that a lot more work is needed to develop the early animal research.

Alzeheimer Scotland says about 65,000 people have the condition in Scotland and the number of people affected will pass 100,000 by 2029.

Scientists in the US screened thousands of compounds for their brain-protective properties. They identified one called P7C3 that had dramatic effects on ageing rats and genetically engineered mice.

The molecule spurred on the growth of new neurons in a part of the brain vital to memory, according to the research, which has been reported in the journal Cell.

It significantly improved the ability of ageing rats to swim through a water maze – a standard test of memory-dependent learning – and assisted the birth of brain cells in mice.

Further research showed that a derivative of the compound, called A20, had an even bigger impact on the brain.

The scientists are still trying to find out how the drugs work. They appear to prevent a process called apoptosis, which causes cells to self-destruct.

Thomas Insel, director of the US body that funded the work, the National Institute of Mental Health (NIMH), said: “This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease.”

A key factor is that P7C3 can be swallowed, rather than having to be injected.

Dr Steven McKnight, one of the research leaders from the University of Texas Southwestern Medical Centre in ­Dallas, said: “The neuroprotective compound, called P7C3, holds special promise because

of its medication-friendly properties.

“It can be taken orally, crosses the blood-brain barrier with long-lasting effects, and is safely tolerated by mice during many stages of development.”

The “blood-brain barrier” is a biological wall designed to prevent potentially harmful substances entering the brain.

Drugs that target the brain have to overcome this obstacle if they are to be effective.

Scientists now know that the adult brain is “plastic” and capable of regenerating itself under the right conditions.

Nerve growth in the hippocampus, the brain’s memory ­centre, can potentially stave off mental decline.

However, even in a normal brain most of the newborn neurons die during the month or more it takes them to develop and become “wired in”.

Newborn hippocampus neurons are known to fare much worse in people with age-related disorders such as Alzheimer’s, which cause the runaway death of nerve cells.

The scientists set about trying to find compounds that might protect vulnerable growing neurons in the dentate gyrus, a key area of the hippocampus.

They found that giving P7C3 to the genetically engineered adult mice reduced the death of newborn cells.

It prevented the stunted growth of branch-like neuronal extensions, and thickened an abnormally thin layer of cells by 40%.

When the compound was fed to ageing rats, they outperformed other rodents in the water maze test.

This was traced to a level of newborn neurons in the dentate gyrus of the treated animals, which was three times higher than normal.

Other compounds with structural similarities to P7C3 may also be worth investigating, said the scientists.

At least two of these have already been looked at as potential Alzheimer’s treatments. The P7C3 derivative A20 was 300 times more potent than one of these drugs, Dimebon, which failed in a Phase III patient trial, the researchers said.

They wrote: “The speculative idea that these chemicals share a common mode of action will only be rigorously tested upon identification of their molecular target.”

http://www.dimebonalzheimers.com/

Dimebon Over Counter Treatment

One Hour Canada

Furnasman New Homes

Furnasman Winnipeg

  • Share/Bookmark
Blog Traffic Exchange Related Websites

The one-a-day pill that could finally halt Alzheimer’s

Saturday, August 14th, 2010

A single daily pill that stops Alzheimer’s in its tracks is being developed by scientists.

The drug, discovered by sheer luck according to researchers, stops brain cells from dying, boosting their numbers and sharpening memory.

Given early enough, it could prevent sufferers from reaching the devastating final stages of the disease, in which they lose the ability to walk, talk and even swallow.

Some experts believe it could even be a cure.

Alzheimer’s and other forms of dementia blight the lives of more than 800,000 Britons, and the number of cases is expected to double within a generation.

With the death of brain cells at the core of Alzheimer’s, the breakthrough brings fresh hope.

U.S. researchers found the drug after testing more than 1,000 chemicals on mice. Dr Steven McKnight said: ‘We really didn’t know if the screen would turn up a favourable compound or not. It was blind luck.’ In tests, the drug, known only as P7C3, boosted the production of cells in a part of the brain critical to memory.

Dr McKnight, of the University of Texas Southwestern, said: ‘These mice are bad at making new neurons. The question was, “Can you fix that?” And the answer to that was “yes”.’ Not only did the new brain cells form, but they also worked properly, the journal Cell reports.

In other experiments, the drug improved memory in ageing rats, making it easier for them to find their way through a maze. Further research showed that a derivative of the compound, called A20, had an even bigger impact on the brain.

Dr McKnight and colleague Dr Andrew Pieper are still trying to find out how the drug works.

It appears to prevent a process called apoptosis, which causes cells, including many newly-formed brain cells, to self-destruct.

It also seems to give a boost to the mitochondria, the tiny batteries that power cells.

The research team hope the chemical can be turned into a once-a-day pill. Those with multiple sclerosis, Huntington’s disease and schizophrenia might also benefit. Dr McKnight said: ‘The neuroprotective compound P7C3 holds special promise because of its medicationfriendly properties.

‘It can be taken orally, crosses the blood-brain barrier with long-lasting effects, and is safely tolerated by mice during many stages of development.’

The blood-brain barrier is a biological ‘wall’ designed to prevent potentially harmful substances entering the brain.

Thomas Insel, director of the U.S. body that funded the work, the National

Institute of Mental Health, said: ‘This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease.’

But the development of an effective pill does not bring with it a guarantee of treatment on the NHS, with current drugs severely rationed.

One, Aricept, costs just £2.50 a day but is rationed to those with ‘ moderate’ illness.

Rebecca Wood, of the Alzheimer’s Research Trust, said: ‘Any research that moves us towards a way of preserving the life of cells in the brain is worthy of attention. Steps must now be taken to research whether the compound can be used beneficially and safely in people.’

http://www.dimebonalzheimers.com/

Dimebon Over Counter Treatment

Boonstraonehour

Air Quality’s One Hour

Auto Transport Montreal  and Car Carrier GTA Ontario

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Protein may help restore lost movement after stroke U.S. researchers have found that a supplemental protein may help restore impaired mobility of people who suffer from a stroke. Naturally occurring in humans, the protein has proved to work...
  • Stem cells can help reverse hearing loss Image via Wikipedia There's a medical breakthrough for the deaf. Scientists at United Kingdom's Sheffield University have created stem cells from embryos to replace damaged cells in the inner ear...
  • MonaVie Does Not Treat Medical Conditions Every MonaVie distributor will agree... MonaVie is just fruit. With that being the case it's worth looking at what the benefits of fruit are. To get to the point, let's...
  • Doubt Cast on New Alzheimer's Drugs  Do the new Alzheimer's drugs really work?Apparently not, according to some recent Italian studies.Three drugs, Aricept, Exelon, and Reminyl are being prescribed to patients who are in the  mild to...
  • Memory Exercises There are some easy things that you can add to your daily life to keep your memory sharp and encourage your brain cells to stay active. These aren't memory exercises...
  • Diabetes Medication May Get New Life as Cancer Treatment The drug metformin, a mainstay of diabetes care for 15 years, may have a new life as a cancer treatment, researchers said. In a study in mice, low doses of...
  • Addictions - Legal and Healthy? I found this blog post very interesting...I have always been drawn to people and human energy.  It was not until I hit my 30's that I realized I should pay...

A pill to make you smarter? Drug grows brain cells

Tuesday, August 10th, 2010

Researchers have found a drug that can help the brain grow new cells and said their study may lead to ways to improve experimental Alzheimer’s drugs.

The researchers’ work, done on rodents, builds on findings that all mammals, including humans, make brain cells throughout their lives. Most of these die, but this drug helps more of the baby cells survive and grow to become functioning brain cells.

“We make new neurons every day in our brain,” Andrew Pieper of the University of Texas Southwestern Medical Centre in Dallas who worked on the study, said in a telephone interview. “What our compound does in allow more of them to survive.”

The compound is called P7C3 for now, and the researchers have already started tweaking it to make it more effective. They said it seems safe and appears to work even when taken as a pill.

The compound is similar to Medivation Inc (MDVN.O) and Pfizer Inc’s (PFE.N) experimental Alzheimer’s drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.

It is also similar to some compounds owned by Serono, the researchers said.

Dimebon, originally a Russian-made antihistamine also known as latrepirdine, failed in a clinical trial for Alzheimer’s disease in March.

“For the sake of patients suffering from Alzheimer’s disease, it is hoped that the apparently marginal clinical utility of Dimebon might be enhanced by improvements in both its potency and ceiling of proneurogenic, neuroprotective efficacy,” the researchers wrote.

“If so, our work offers concrete assays for the development of improved versions of these neuroprotective drugs.”

Alzheimer’s gradually destroys the brain and affects 26 million people globally. Drugs, such as Pfizer’s Aricept, improve symptoms only minimally.

OLD RATS, NEW TRICKS

The researchers went through 1,000 representative compounds from 300,000 chemicals, pooled them and administered them to mice. They then dissected the brains to see whether any of the mice had made new cells in the hippocampus, a region of the brain associated with learning and memory.

They eventually narrowed the field to P7C3.

When they gave it to old rats for two months, the elderly rodents did far better than other old rats in learning their way around a water maze.

When dissected, the treated rats turned out to have three times the usual number of newborn neurons in a brain region called the dentate gyrus.

They made a derivative of P7C3 called A20 that worked even better.

When the researchers tested Dimebon and the Serono compounds, they found these drugs also stimulated the growth of new brain cells. Being able to target their effects could lead to better drugs to treat Alzheimer’s and perhaps other diseases that destroy brain cells like strokes and amyotrophic lateral sclerosis, also know as ALS or Lou Gehrig’s disease.

“This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease,” said Dr. Thomas Insel, director of the National Institute on Mental Health, which helped pay for the study.

http://www.dimebonalzheimers.com/

Dimebon Over Counter Treatment

One Hour Canada

Furnasman New Homes

Furnasman Winnipeg

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Will You Get Alzheimer's?  67 out of every 1,000 older Americans have been diagnosed with some form of Alzheimer's. By 2050, more than 26 million people worldwide will be living with Alzheimer's disease.  Will you...
  • Books: Get Your Motivation Back! With January over, many people will be either be well on the way to making their new years resolutions or have already ditched them. If you're part of the first...
  • BioTime Commences Shipment of Stem Cell Research Products to Millipore Image via Wikipedia BioTime Inc.announced today that it has initiated shipments of stem cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement...
  • Virus shown to cause obesity Researchers now have proof that a virus may be involved in human obesity, according to a paper just published in the International Journal of Obesity. A virus had been shown...
  • Does Mel Gibson potentially have a brain injury? Does Mel Gibson potentially have a brain injury? We've all read the headline news about athletes and their unrelentingly agressive behavior on and off the field. Particularly disturbing is when...
  • Using Rosehip Oil As an Ingredient in Skin Care Products What is Rosehip oil? Its botanical name is Rosa rubiginosa L. (Synonym R. eglanteria) and it belongs to the family Rosaceae. Its common names include: Wild rose, Sweet Briar, Sweet...
  • Hacker builds $1,500 cell-phone tapping device [/caption] LAS VEGAS – A computer security researcher has built a device for just $1,500 that can intercept some kinds of cell phone calls and record everything that's said. The...

UK Studies to Look at Alzheimer’s, Down Syndrome

Monday, July 12th, 2010

The University of Kentucky Sanders-Brown Center on Aging is looking for two groups of patients to help learn more about Alzheimer’s disease.

One study will examine how a new drug can supplement existing treatment; the other focuses on Down syndrome and Alzheimer’s.

The first study is looking at how the drug Dimebon can help Alzheimer’s patients already taking Aricept.

Because Alzheimer’s is a complex disease, patients sometimes need multiple drugs to address their symptoms, said Dr. Gregory Jicha, assistant professor of neurology at the UK College of Medicine. Aricept is one of the most widely prescribed Alzheimer’s drugs in the country.

Dimebon is thought to improve the mitochondrial function in brain cells, preventing damage. Cell parts called mitochondria are critical to brain function because they are the primary source of cells’ energy.

Aricept appears to enhance the brain’s concentration of acetylcholine, an enzyme crucial to memory and learning, he said.

Jicha said a good candidate for this study would have relatively mild symptoms. “In the early stage of the disease people can understand what the trial means and participate in the decision to help find better medicine and potential cures for Alzheimer’s,” he said.

The UK effort is part of an international project that will evaluate more than 1,000 patients, including at least a dozen at UK.

Another new research project looks at the connection between Down syndrome and Alzheimer’s. The $2.4 million, five-year study will look at how Down syndrome and Alzheimer’s disease may affect a person’s memory and thinking as they get older, said Dr. Elizabeth Head, who will lead the study.

The study will recruit and follow 40 people older than 35 with Down syndrome. In addition, 10 to 12 people with Down syndrome and Alzheimer’s disease will be recruited for a single research session.

The Down syndrome patients without Alzheimer’s will be tested every six months.

Head said the life expectancy of Down syndrome patients has increased dramatically over the years but the services they need as they age have not kept up. “There is really not a whole lot out there for them,” she said. “They are a little underserved.”

At the same time, she said, Down syndrome patients offer a unique opportunity to study Alzheimer’s. The chromosomal abnormality that creates Down syndrome also results in the overproduction of the protein that causes Alzheimer’s.

“They make a protein that causes Alzheimer’s disease. They are making too much of it from birth,” she said.

Most middle-age Down syndrome patients have full-blown Alzheimer’s disease in their brain but not all of them develop dementia, she said. Understanding how they continue to function could be key to helping others with Alzheimer’s, she said.

More than 400,000 people in the United States have Down syndrome. Overall, 50 percent of people with Down syndrome age 55 and older may have Alzheimer’s disease.

Overall, some 5.3 million in the United States have Alzheimer’s. According to the Alzheimer’s Association that number is expected to increase dramatically as the baby boomer generation continues to age.

Jicha said it’s possible if a patient isn’t right for one of these studies, several more are currently underway that might be a better fit.

“We always have a variety of opportunities,” he said. “Every study has a different number demands.”

“We are trying to build an army to fight Alzheimer’s,” he said. “That army doesn’t just include doctors and researchers but battalions of patients willing to pick up these new weapons to join the fight.”

Fort McMurray Auto Financing Online

Furnasman One Hour UV Lights

Dimebon Online

http://www.dimebonalzheimers.com/

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Other Promising Drugs Medications for Treatment of Alzheimer's Disease

Monday, August 17th, 2009

Borgess Research Institute has 12 patients participating in drug trials for an Alzheimer’s drug that appears to slow the onset of the disease, and it is looking for more.

Patients are still being accepted for the Phase 3 trial, first announced here last February and part of a nationwide study, said Dr. Phillip Green, a Borgess researcher overseeing local testing. While 12 patients from across southwestern Michigan have enrolled, Green said the institute hopes to have a total of 16 to 20 participants.

Testing began here in June. So far, local researchers have seen no complications from the drug.
Who is eligible for the study

Participants in the Alzheimer’s drug trial must be age 50 to 88, have a diagnosis of probable Alzheimer’s disease and mild to moderate symptoms and have caregivers who are willing to be involved in the study.

At this point, the study has been closed to patients carrying the apolipoprotein E4 aliel, one of the most common genetic markers for the disease.

Participants in the trial receive intravenous infusions of the drug bapienuzumab every three months for a period of 18 months. Researchers will give patients screening tests to evaluate their cognitive skills, daily-living skills and behavioral patterns.

About 60 percent of participants will receive the drug, while the other 40 percent will receive a placebo.

FOR MORE INFORMATION

• Call the Borgess Research Institute at 226-4803 or visit the Web site.

Alzheimer’s is a disease that kills brain cells, causing problems with memory, thinking and behavior and eventually causing death.

It is believed to be caused by the buildup of two substances in the brain: plaques and tangles. Plaques build up between nerve cells and contain beta-amyloid, a protein fragment. Tangles form inside dying cells and are twisted fibers of another protein.

The researchers are studying bapienuzumab, also known as AAB-001, which breaks down the amyloids in the plaques so they can be eliminated from the brain.

“In initial work, 90 percent of amyloid burden was removed from brains of genetically engineered mice,” Green said.

Researchers hope to work with patients in the early stages of the disease, because “once you start establishing plaques, it seems to set up the further progression of change in the brain in terms of the neurofibrillary tangles,” Green said. “We need to stop the tangles from getting started.”

Green said it is estimated that nearly 5.2 million Americans have Alzheimer’s but that only 50 percent of those cases are diagnosed. In addition, only half of the diagnosed patients are receiving appropriate drug therapy, he said.

The lack of early diagnosis hampers researchers looking for patients with early symptoms, he said. Often, those experiencing symptoms such as problems with memory simply attribute them to normal aging patterns, he said.

Other promising drugs

Green said two other promising Alzheimer’s drugs are in various stages of testing.

Dimebon is an older medication that was used as an antihistamine in Russia. It appears to be a neuroprotector that provides stabilization and improvement of behavior and cognition symptoms associated with Alzheimer’s. Green said he is hoping to get a Dimebon trial at Borgess.

http://www.mlive.com/living/kalamazoo/index.ssf/2009/01/borgess_seeking_more_patients_1.html

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark

Alchohol Intake & Ingestion – Good or Bad When it Comes to Alzheimer's Disease

Wednesday, April 15th, 2009

When it comes to alcohol indeed it can be said that no one is more of an expert than the “Schemendrick” himself – Mr Tuesday value village .   It appears overall that while heavy drinking is devastating to brain cells of the human body , that moderate consumption can be helpful to brain activity and mental health overall.  A little may be good in moderation yet more or much more is not good.  Yet with those who like to drink or “have a drinking problem” or problem one drink is off to the races.  Its as if one drink is not enough nor is 1,000 drinks.  Its an endless case of “chasing the dragon’s tail”.

Several large European studies have found and demonstrated that that people who drank modestly  ( one to two drinks a day ) , had a much lower risk overall for developing memory loss and Alzheimer’s disease than those who did not drink what so ever or at all.   This is as opposed and compared to those who drank heavily.

Studies done in the united states  ( where generally “moderate”  drinking is defined as those who  drink two drinks a day , in the case of men , and one drink a day in the case of women) ,  have shown and demonstrated overall that study subjects who drink wine  actually lower their chances overall and statistically for developing these problems.

Yet it is a question of personal choice and evaluation for the individuals involved.   Its always a balance of the benefits in each case versus the potential and real health costs  and costs to the individuals health overall.

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • More Essentials for Good Health Here is a look at ten essential tips for good health, which involve diet, weight loss, good nutrition, fitness and movement and other aspects of your health. Tie these ten...
  • Trying to lose weight? Drink more water Forget diet pills and cleanses. A new study suggests that an effective weight-loss aid is available straight from your kitchen sink. Drinking two 8-ounce glasses of water before breakfast, lunch,...
  • Coffee Sets Collectibles -> Housewares-and-Kitchenware -> Tableware A coffee set is a highly collectible item, whether you’re looking for a traditional Turkish coffee set that’s unique, or a modern-day coffee set designed...
  • Fluoride still not safe, despite tooth-decay data The headline of a recent news post from Reuters reads, Flouride in tap water may help older teeth too. To the casual reader, this headline seems to indicate that protecting...
  • MonaVie Does Not Treat Medical Conditions Every MonaVie distributor will agree... MonaVie is just fruit. With that being the case it's worth looking at what the benefits of fruit are. To get to the point, let's...
  • Avoiding Dangers in the Kitchen pt 2 Once you're done here, you are going to want to move on to the remainder of the kitchen like so: You need to learn how to read your food labels...
  • American MonaVie and Canadian MonaVie are Different? I noticed this in another discussion today. MonaVie is different in the US and Canada. it's worth noting the inconsistency across the labels. The US label clearly shows that it's...